Jonathan Haldeman is a molecular engineer with over 15 years of laboratory experience in both academic and industrial environments. Currently, they serve as a Principal Scientist at Janssen Pharmaceutical Companies of Johnson & Johnson, focusing on the development of gene therapy technologies. Jonathan's prior research at the Duke Molecular Physiology Institute centered on uncovering therapeutic targets for type 2 diabetes through the study of pancreatic islet beta-cell signaling pathways. They have also contributed to the creation of novel modular cloning platforms for genetic manipulation and have engaged in numerous interdisciplinary collaborations throughout their career. Jonathan holds a PhD from Duke University and a Bachelor of Science degree from Millersville University of Pennsylvania.
Location
Lansdale, United States
This person is not in any teams
This person is not in any offices